BioSpace News Archive

Pharmacy Quality Alliance (PQA) has awarded Blue Shield of California the 2019 Quality Improvement Award for its Medicare Advantage Prescription Drug Plan.

Following meetings with then-Commissioner Scott Gottlieb and senior leadership from the Center for Drug Evaluation and Research on the role of CROs and technology companies in designing and implementing risk-based monitoring (RBM) of clinical trials, the Association of Clinical Research Organizations (ACRO) this week submitted extensive comments on recent FDA Guidance.

The AI Foundation, a leader in creating foundational AI technologies, products and services to unlock the human potential, as well as Guardian AI to protect society from its risks, has partnered with the Technical University of Munich’s Visual Computing Lab, providing resources for world renowned scientist Professor Matthias Niessner and his team to continue research in artificial intelligence, deep learning and computer vision.

Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from the first-in-human study of its investigational RheOxTM device will be presented at the 2019 American Thoracic Society (ATS) International Conference, occurring May 17-22, 2019 in Dallas, Texas.

Inflammatix announced today that it has been named a finalist for the American Association for Clinical Chemistry’s (AACC) Disruptive Technology Award for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis.

New Jersey’s nonprofit hospitals contributed $2.83 billion in community benefit support within their local communities in 2017, a commitment that includes free and discounted care along with support for social determinants of health including nutrition, housing and education.

On May 15, 2019, CEN Biotech, Inc. entered into a Non-Binding Term Sheet with Caduceus Software Systems Corp., a Wyoming corporation, which was reviewed and approved by the Board of Directors of CEN on May 15, 2019.

Amgen will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City.

Neurocrine Biosciences, Inc. announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible tardive dyskinesia, an involuntary movement disorder.

Egalet Corporation reported financial results for the first quarter ended March 31, 2019 and announced it will change its name to Zyla Life Sciences in the coming weeks.